Home »
Adjuvant immunotherapy conferred a 93% survival at 1 year for patients with resectable melanoma at the highest risk of relapse
The analysis captures the first survival data from the National Cancer Database (NCDB) since the FDA’s 2015 approval of ipilimumab (Yervoy) following curative intent surgery in stage…